New drug MN-001 tested for scarred lungs in tiny trial
Disease control
Completed
This study tested an experimental drug called MN-001 (tipelukast) in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants took either the drug or a placebo twice daily for six months, then everyone could take the drug for an…
Phase: PHASE2 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC